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Original article
Angiotensin (Ang) II, the main component of the renin–
angiotensin system, plays an important role in the pathogen-
esis of cardiovascular diseases including hypertension.1 Ang 
II-induced hypertension is due to its action in the subfor-
nical organ (SFO) of circumventricular organs resulting in 
increased oxidative and endoplasmic reticulum (ER) stress 
and activity of the sympathetic nervous system.2–4 There is 
a substantial body of evidence that increased reactive oxy-
gen species (ROS) production and activation of immune 
cells mediate Ang II-induced hypertension and associated 
pathogenesis.5–8 Ang II also increases the activity of cyto-
solic phospholipase A2 (cPLA2) resulting in arachidonic 
acid (AA) release from tissue phospholipids.9,10 AA is 
metabolized by cyclooxygenase (COX), lipoxygenase, and 
cytochrome P450A into various eicosanoids with prohyper-
tensive and antihypertensive effects.11–13 Prostaglandin (PG) 
E2, by stimulating EP1 and EP3 receptors,14 and throm-
boxane A2,11 12-, and 20-HETE,12,13,15,16 by their vascular 
actions, exert prohypertensive effects. On the other hand, 
PGE2  through stimulation of EP2 and EP4 receptors,14,17 
PGI2,11 and epoxyeicosatrienoic acids13,18 produce vasode-
pressor effects. One or more of the eicosanoids contribute to 
Ang II-induced hypertension.19–22 Ang II-salt hypertension is 
also dependent on COX-1 activity.23 Intracerebroventricular 
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BACKGROUND
Recently, we reported that angiotensin II (Ang II)-induced hyper-
tension is mediated by group IV cytosolic phospholipase A2α 
(cPLA2α) via production of prohypertensive eicosanoids. Since Ang 
II increases blood pressure (BP) via its action in the subfornical organ 
(SFO), it led us to investigate the expression and possible contribu-
tion of cPLA2α to oxidative stress and development of hypertension 
in this brain area.
METHODS
Adenovirus (Ad)-green fluorescence protein (GFP) cPLA2α short hair-
pin (sh) RNA (Ad-cPLA2α shRNA) and its control Ad-scrambled shRNA 
(Ad-Scr shRNA) or Ad-enhanced cyan fluorescence protein cPLA2α 
DNA (Ad-cPLA2α DNA) and its control Ad-GFP DNA were transduced 
into SFO of cPLA2α+/+ and cPLA2α−/− male mice, respectively. Ang II 
(700  ng/kg/min) was infused for 14  days in these mice, and BP was 
measured by tail-cuff and radio telemetry. cPLA2 activity, reactive 
oxygen species production, and endoplasmic reticulum stress were 
measured in the SFO.
RESULTS
Transduction of SFO with Ad-cPLA2α shRNA, but not Ad-Scr shRNA in 
cPLA2α+/+ mice, minimized expression of cPLA2α, Ang II-induced cPLA2α 
activity and oxidative stress in the SFO, BP, and cardiac and renal fibro-
sis. In contrast, Ad-cPLA2α DNA, but not its control Ad-GFP DNA in 
cPLA2α−/− mice, restored the expression of cPLA2α, and Ang II-induced 
increase in cPLA2 activity and oxidative stress in the SFO, BP, cardiac, 
and renal fibrosis.
CONCLUSIONS
These data suggest that cPLA2α in the SFO is crucial in mediating Ang 
II-induced hypertension and associated pathogenesis. Therefore, devel-
opment of selective cPLA2α inhibitors could be useful in treating hyper-
tension and its pathogenesis.
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administration of PGE2 increases sympathetic activity, vaso-
pressin release, and blood pressure (BP),24 and the hypotha-
lamic paraventricular excitation and sympathetic activation, 
via EP3 receptors.25 Injection of PGE2 into the rostral ven-
trolateral medulla also causes sympathoexcitation and pres-
sor response via the EP3 receptor.26 These observations 
suggest that the release of AA by cPLA2, the rate-limiting 
step in the synthesis of eicosanoids, could be critical for Ang 
II-induced ROS production and hypertension.
Several types of mammalian cPLA2 enzymes have been 
identified;27 however, group IV cPLA2 shows high selectivity 
for AA-containing phospholipids.27,28 cPLA2 consists of six 
isoforms (cPLA2α, -β, -γ, -δ, -ε, and -ζ) with only 30% homol-
ogy, tissue distribution, and enzymatic activity.28 In a previous 
study, we showed that the selective cPLA2α gene disruption 
prevented Ang II-induced increase in urinary levels of eicos-
anoids, hypertension, and associated cardiovascular, renal 
dysfunction and inflammation, suggesting that prohyperten-
sive eicosanoids generated from AA mediate Ang II-induced 
hypertension.29,30 However, the site of eicosanoids produced by 
group IV cPLA2α, which mediate Ang II-induced hyperten-
sion, is not known. Since numerous tissues including cardio-
vascular, renal, brain, and immune cells produce eicosanoids 
that exert their effect locally, these should be formed from AA 
released by cPLA2α and act at the site of action of Ang II.
PLA2 is distributed in several regions of the brain,31 and Ang 
II increases expression of PLA2 in the organum vasculosum of 
the lamina terminalis, paraventricular nucleus (PVN), nucleus 
of the solitary tract, and middle cerebral artery.32 The demon-
stration that Ang II-induced oxidative stress and hypertension 
is mediated via the COX-1-derived metabolite PGE2 via EP1 
receptor in the SFO33 raises the possibility that cPLA2α in the 
SFO might be critical for the action of Ang II to increase oxi-
dative stress and BP. To test this hypothesis, we examined the 
localization and the effect of cPLA2α depletion in the SFO by 
transduction with adenovirus (Ad)-green fluorescence protein 
(GFP)-cPLA2α short hairpin (sh) RNA (Ad-cPLA2α shRNA). 
We also examined its reconstitution in knockout (cPLA2α−/−) 
mice by transduction with Ad-enhanced cyan fluorescence 
protein (ECFP)-cPLA2α DNA (Ad-cPLA2α DNA) in the 
SFO. We then examined the effect of these probes on Ang 
II-induced hypertension and associated pathogenesis in mice. 
Our results show that depletion of cPLA2α in the SFO prevents 
Ang II-induced hypertension, ROS and ER stress, and asso-
ciated pathogenesis, while expression of cPLA2α in cPLA2α−/− 
mice restores these deleterious effects of Ang II.
MATERIALS AND METHODS
Details for Materials and Methods section are in the 
online-only Data Supplement.
Animal experiments
All animal experiments were performed using protocols 
approved by the University of Tennessee Health Science 
Center Institutional Animal Care and Use Committee 
according to the National Institutes of Health Guide for the 
Care and Use of Laboratory Animals. Experiments were 
conducted in 8- to 10-week-old, 20- to 25-g body weight, 
wild-type (cPLA2α+/+), and cPLA2α gene disrupted homo-
zygous (cPLA2α−/−) male mice on BALB/c background. 
Ang II (700 ng/kg/min) or saline (vehicle) was infused for 
14  days with micro-osmotic pumps implanted subcutane-
ously. Systolic BP (SBP) was measured by the noninvasive 
tail-cuff method, or mean arterial pressure (MAP) daily by 
radio telemetry. However, 2 to 3 out of 6 cPLA2α−/− BALB/c 
mice implanted with radio transmitters did not survive 
more than 8 to 10 days. We did not encounter this problem 
in male C57BL/6 mice. Therefore, we first confirmed the BP 
measurements recorded by the tail-cuff method in the male 
C57BL/6 mice to that obtained in BALB/c mice and then 
used cPLA2α−/− mice on the C57BL/6 background to further 
confirm BP measurements by radio telemetry.
Statistical analysis
One or 2-way analysis of variance was used to analyze the 
data, Tukey’s post hoc test for multiple comparisons, and 
student’s t-test to compare the difference between 2 groups. 
The values obtained from at least 3 to 5 different experiments 
were expressed as the mean ± SEM, P <0.05 was considered 
statistically significant.
RESULTS
cPLA2α gene disruption in SFO of cPLA2α+/+ mice with 
Ad-cPLA2α shRNA attenuated Ang II-induced increase in 
BP and cPLA2 activity, but not expression of cPLA2α, and 
reduced collagen accumulation in the heart and kidney
To determine the contribution of cPLA2α in the SFO to 
Ang II-induced hypertension, the SFO was transduced with 
Ad-cPLA2α shRNA. Infusion of Ang II by micro-osmotic 
pumps implanted subcutaneously increased SBP, measured by 
tail-cuff, in male cPLA2α+/+ BALB/c and cPLA2α+/+ C57BL/6 
mice (Supplementary Figure S1A and B). Transduction of 
the SFO with Ad-cPLA2α shRNA but not its Ad-Scr shRNA 
prevented Ang II-induced increase in SBP in male cPLA2α+/+ 
BALB/c mice (Figure 1a). SBP was not altered by the adenovi-
ruses during vehicle infusion (Figure 1a). Ad-cPLA2α shRNA 
but not its Ad-Scr shRNA also prevented Ang II-induced 
increase in mean arterial BP (MAP) measured by radio telem-
etry in cPLA2α+/+ C57BL/6 mice (Figure 1b). Transduction of 
the SFO with Ad probes was confirmed by expression of GFP 
in the SFO (Supplementary Figure S2A). cPLA2α expression in 
the SFO was abolished by Ad-cPLA2α shRNA but not Ad-Scr 
shRNA as determined by cPLA2α immunoreactivity using 
mouse anti-cPLA2 antibody in BALB/c mice (Figure 1c and d), 
and by RT-PCR in BALB/c and C57BL/6 mice (Supplementary 
Figures S2B and S3A, respectively). Ang II also increased cPLA2 
activity measured by increased phospho-cPLA2 immunoreac-
tivity in the SFO transduced with Ad-Scr shRNA, but not with 
Ad-cPLA2α shRNA in BALB/c (Figure 1c and d), and C57BL/6 
mice (Supplementary Figure S3B and C). Transduction of the 
SFO with Ad-Scr shRNA or Ad-cPLA2α shRNA did not alter 
expression of cPLA2α in the PVN, heart, and kidney examined 
in BALB/c mice (Supplementary Figure S2C–E).
Ang II is known to cause cardiac and renal fibrosis.29,30 
To determine if the alteration in cPLA2α expression in the 
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SFO also affects the action of Ang II on cardiac and renal 
fibrosis, we examined the accumulation of collagen in these 
tissues in BALB/c mice. cPLA2α gene disruption in the SFO 
of cPLA2α+/+ mice by transduction with Ad-cPLA2α shRNA 
but not its Ad-Scr shRNA control infused with Ang II mini-
mized accumulation of collagen in the heart and kidney 
(Supplementary Figure S4A and B).
Transduction with Ad-ECFP-cPLA2α DNA, but not Ad-GFP 
DNA in the SFO of cPLA2α−/− mice restored the effect of Ang 
II to increase BP
Ang II failed to increase BP in cPLA2α−/− BALB/c mice 
(Supplementary Figure S1). Transduction with Ad-cPLA2α 
DNA but not Ad-GFP DNA in the SFO of cPLA2α−/− 
BALB/c mice restored the effect of Ang II to increase SBP 
measured by tail-cuff (Figure  2a). Ang II also increased 
MAP measured by radio telemetry in cPLA2α−/− C57BL/6 
mice transduced with Ad-cPLA2α DNA, but not Ad-GFP 
DNA in the SFO (Figure  2b). The localization of ECFP-
cPLA2α and GFP in the SFO transduced with Ad-cPLA2α 
DNA and Ad-GFP DNA, respectively, was confirmed 
by their fluorescence (Supplementary Figure S5A), and 
by RT-PCR in BALB/c (Supplementary Figure S5B) 
and C57BL/6 mice (Supplementary Figures S5A and S6A), 
and by immunohistochemistry using anti-cPLA2 antibody 
in BALB/c (Figure 2c and d) and C57BL/6 (Supplementary 
Figure S6B and C) mice. Ang II did not alter expression of 
Figure 1. cPLA2α gene disruption in subfornical organ (SFO) of cPLA2α+/+ mice with adenovirus (Ad)-green fluorescence protein (GFP)-cPLA2α shirt hair-
pin (sh) RNA (Ad-cPLA2α shRNA) abrogates Ang II-induced increase in blood pressure (BP) and cPLA2 phosphoimmunoreactivity. Ad-GFP scramble (Scr) 
shRNA (Ad-Scr shRNA) or Ad-cPLA2α shRNA was transduced into SFO. (a) systolic blood pressure (SBP) was measured by tail-cuff in BALB/c mice. (b) Mean 
arterial blood pressure (MAP) was measured by radio telemetry in C57BL/6 mice. (c) Expression of cPLA2, and its activity measured by its phosphorylation 
in SFO of BALB/c mice by immunohistochemical method. Scale bars: 50 µm. (d) Quantified data. Data are expressed as mean ± SEM. n = 5 per group. *, **P 
<0.05, Ad-Scr shRNA-Ang II vs. Ad-Scr shRNA-Veh (Vehicle); †P < 0.05, Ad-cPLA2α shRNA-Ang II vs. Ad-Scr shRNA-Ang II in cPLA2α+/+ BALB/c mice (a) and 
cPLA2α+/+ C57BL/6 mice (b). #P < 0.05, Ad-cPLA2α shRNA vs. Ad-Scr shRNA.
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cPLA2α, but it increased the cPLA2 activity, measured by 
phospho-cPLA2 immunoreactivity in the SFO transduced 
with Ad-cPLA2α DNA, but not Ad-GFP DNA in BALB/c 
mice (Figure  2c and d). cPLA2α mRNA expression in 
the PVN, heart, and kidney that was absent in cPLA2α−/− 
BALB/c, was not altered by transduction of the SFO with 
Ad-GFP DNA or Ad-cPLA2α DNA during infusion of Ang 
II (Supplementary Figure S5C–E).
We also determined the effect of Ang II on collagen 
accumulation in the heart and kidney of BALB/c cPLA2α−/− 
mice transduced with Ad-cPLA2α DNA and Ad-GFP DNA 
in the SFO, and found collagen accumulation in the former 
but not the latter group of mice (Supplementary Figure 
S7A and B).
Transduction of SFO with cPLA2α shRNA in cPLA2α+/+ mice 
attenuated, and Ad-cPLA2α DNA in cPLA2α−/− mice restored 
Ang II-induced increase in ROS production
These studies were conducted in BALB/c mice that were 
infused with Ang II or its vehicle for the measurement of 
BP as described above. Infusion of Ang II also stimulated 
the production of ROS as indicated by enhanced 2-hydroxy-
ethidium fluorescence in the SFO generated after staining 
with dihydroethidium as described,4 in cPLA2α+/+ mice but 
not in cPLA2α−/− mice (Figure  3a and b). Transduction of 
the SFO with Ad-cPLA2α shRNA but not its Ad-Scr shRNA 
inhibited dihydroethidium staining (Figure  3c and d) in 
cPLA2α+/+ mice. Infusion of Ang II in cPLA2α−/− mice failed 
Figure 2. cPLA2α gene transduction in subfornical organ (SFO) of cPLA2α−/− mice with adenovirus (Ad)-enhanced cyan fluorescence protein (ECFP)-
cPLA2α DNA (Ad-cPLA2α DNA) restores Ang II-induced increase in blood pressure (BP) and cPLA2 activity. Ad-green fluorescence protein (GFP) (Ad-GFP) 
DNA or Ad-cPLA2α DNA was transduced into SFO. (a) Systolic blood pressure (SBP) was measured by tail-cuff in cPLA2α−/− BALB/c mice. (b) Mean arterial 
blood pressure (MAP) was measured by radio telemetry in cPLA2α−/− C57BL/6 mice. (c) Expression, and activation of cPLA2 in SFO of BALB/c mice were 
measured by immunohistochemical method. Scale bars: 50 µm. (d) Quantified data. Data are expressed as mean ± SEM. n = 5 per group. *, **P < 0.05, 
Ad-cPLA2α DNA-Ang II vs. Ad-cPLA2α DNA-Veh (vehicle); †P < 0.05, Ad-cPLA2α DNA-Ang II vs. Ad-GFP DNA-Ang II in cPLA2α−/− BALB/c and C57BL/6 mice. 
#P < 0.05, Ad-cPLA2α DNA vs. Ad-GFP DNA.
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to increase dihydroethidium staining, whereas transduction 
with Ad-cPLA2α DNA, but not Ad-GFP DNA in the SFO of 
these mice restored the effect of Ang II to increase dihydro-
ethidium staining (Figure 3e and f).
Ang II increased ER stress marker expression in SFO Of 
cPLA2α+/+ but not cPLA2α−/− mice
Ang II also increased ER stress as indicated by increased 
mRNA levels of markers of ER stress glucose-related pro-
tein 78 (GRP78), and C/EBP homologous protein (CHOP) 
in cPLA2α+/+ BALB/c mice (Figure 4a). Infusion of Ang II in 
cPLA2α−/− mice did not induce mRNA levels of GRP78 and 
CHOP (Figure 4b).
Partial cPLA2α gene disruption (cPLA2α+/−) also prevented 
Ang-II-induced increase in BP in mice
Ang II did not increase BP in cPLA2α−/− BALB/c and 
C57BL/6 male mice (Supplementary Figure S1A and B). 
To determine if partial cPLA2α gene disruption reduces 
Ang II-induced increase in BP, we examined its effect in 
heterozygous cPLA2α (cPLA2α+/−) C57BL/6 male mice. 
Ang II (700  ng/kg/min) increased SBP measured by tail-
cuff in cPLA2α+/+ but not cPLA2α+/− C57BL/6 male mice 
(Supplementary Figure S8). cPLA2α mRNA expression 
in the SFO, heart, and kidney of C57BL/6 cPLA2α+/− mice 
was lower (60–80%) than in C57BL/6 cPLA2α+/+ mice 
(Supplementary Figure S9).
DISCUSSION
The major findings of this sudy are that SFO is the principal 
site of action of cPLA2α in mediating the action of Ang II: (i) 
to increase BP; (ii) to stimulate ROS production and ER stress 
in the SFO, and (iii) to cause cardiac and renal fibrosis. These 
findings are based on our demonstration that cPLA2α select-
ively releases AA from tissue phospholipids,27,28 is expressed 
in the SFO, and that Ang II increased cPLA2 activity, as deter-
mined by its phosphoimmunoreactivity without altering 
its expression. However, Ang II has been shown to increase 
expression of phospholipase A2 in the organum vasculosum of 
the lamina terminalis, PVN, nucleus of the solitary tract, and 
middle cerebral artery of the rat.32 Whether this increase in 
phospholipase A2 expression by Ang II in these tissues repre-
sents primarily increased expression of cPLA2α, or other iso-
forms of phospholipase A2 is not known. We have previously 
reported that Ang II increases BP, and sympathetic outflow 
as determined from heart rate variability by power spec-
tral analysis in cPLA2α+/+ but not cPLA2α−/− BALB/c mice.29 
Our demonstration that cPLA2α gene disruption in the SFO 
by Ad-cPLA2α shRNA, but not its Ad-Scr shRNA, reduced 
cPLA2α expression and phospho-cPLA2 immunoreactivity 
and prevented Ang II-induced increase in BP in cPLA2α+/+ 
BALB/c and C57BL/6 mice, suggests that cPLA2α in the SFO 
is critical for Ang II-induced hypertension. Although Ang II 
700 ng/kg/min used in this study would be expected to cause 
the increase in BP by its direct vascular action but it appears 
that cPLA2α in the SFO is primarily responsible for this effect 
of Ang II. Further supporting this conclusion was our finding 
Figure 3. Transduction of subfornical organ (SFO) with Ad-cPLA2α shRNA attenuates, and Ad-cPLA2α DNA restores Ang II-induced increase in reactive 
oxygen species (ROS) production in cPLA2α+/+ BALB/c mice. ROS production was determined using dihydroethidium (DHE). (a) and (b) Ang II-induced 
increase in ROS production in SFO in cPLA2α+/+ but not cPLA2α−/− BALB/c mice. (c) and (d) Transduction of Ad-cPLA2α shRNA in SFO abrogated Ang 
II-induced increase in ROS production in cPLA2α+/+ BALB/c mice. (e) and (f) Transduction of Ad-cPLA2α DNA in SFO restored Ang II-induced increase in ROS 
production in cPLA2α−/− BALB/c mice. Panels a, c, and e, scale bars: 50 µm. Panels b, d, and f, Quantified data (A. U., arbitrary units). Data are expressed as 
mean ± SEM. n = 5 per group. *P < 0.05, Ang II vs. Veh (vehicle); %P < 0.05, cPLA2α−/−-Ang II vs. cPLA2α+/+-Ang II; **P < 0.05, Ad-Scr shRNA-Ang II vs. Ad-Scr 
shRNA-Veh; †P < 0.05, Ad-cPLA2α shRNA-Ang II vs. Ad-Scr shRNA-Ang II; #P < 0.05, Ad-cPLA2α DNA-Ang II vs. Ad-GFP DNA-Ang II.
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that in cPLA2α−/− BALB/c and C57BL/6 mice, reconstitution 
of cPLA2α in the SFO by transduction with Ad-cPLA2α DNA 
but not Ad-GFP DNA increased cPLA2α expression and 
phospho-cPLA2 immunoreactivity, and restored the effect of 
Ang II to increase BP. That cPLA2α protein formed by trans-
duction with Ad-cPLA2α DNA, but not Ad-GFP DNA is cap-
able of releasing AA has been confirmed in vascular smooth 
muscle cells.34 The decrease in the expression of cPLA2α in 
the SFO transduced with Ad-Scr shRNA in cPLA2α+/+ mice, 
and the increase with Ad-cPLA2α DNA in cPLA2α−/− mice 
was selective because its expression in the PVN, heart and 
kidney were not altered in these mice. Ang II stimulates ROS 
production and ER stress in the SFO that leads to an increase 
in BP,3,4 most likely by increasing sympathetic activity.2 The 
increase in BP produced by Ang II 600 ng/kg/min, which is 
comparable to that obtained in the present study by 700 ng/
kg/min of this peptide, is prevented by intracerebral ventricle 
administration of superoxide scavenger Ad-CuZn superoxide 
dismutase.4 Since (i) depletion of cPLA2α by Ad-cPLA2α 
shRNA in the SFO of cPLA2α+/+ mice reduced, and (ii) 
expression of cPLA2α by transduction with Ad-cPLA2α DNA 
in cPLA2α−/− BALB/c mice restored Ang II-induced ROS 
production and ER stress, this suggests that cPLA2α expres-
sion and activity mediates the effect of Ang II on ROS pro-
duction and ER stress. Whether alteration in cPLA2α activity 
by Ang II in SFO also affects the ROS production and ER 
stress in PVN and rostral ventrolateral medulla remains to 
be determined. Ang II is known to produce cardiac and renal 
fibrosis, which is dependent on prohypertensive eicosanoids 
generated by activation of cPLA2α.29,30 Our demonstration 
that Ang II-induced cardiac and renal fibrosis, as indicated 
by collagen accumulation, was minimized by depletion of 
cPLA2α in the SFO by transduction with Ad-cPLA2α shRNA 
in cPLA2α+/+ BALB/c mice suggests that cPLA2α activation 
in the SFO contributes to this action of Ang II. Supporting 
this view was our observation that reconstitution of cPLA2α 
by Ad-cPLA2α DNA in cPLA2α−/− BALB/c mice caused Ang 
II to produce cardiac and renal fibrosis. Whether attenu-
ation of Ang II-induced cardiac and renal fibrosis caused 
by decreased expression of cPLA2α by Ad-cPLA2α shRNA 
in the SFO of cPLA2α+/+ mice and restoration of fibrosis in 
these tissues by expression of cPLA2α by Ad-cPLA2α DNA in 
cPLA2α−/− mice, which could be due to changes in BP and/or 
sympathetic activity, remains to be determined.
cPLA2α activation by Ang II releases AA that is metabo-
lized by COX, lipoxygenase, and cytochrome P450A into 
eicosanoids with prohypertensive and antihypertensive 
effects.11–22 Previously, we reported that prohypertensive 
eicosanoids generated by cPLA2α activation contributed to 
Ang II-induced hypertension and associated cardiac and 
renal pathogenesis.29,30 COX-1 inhibitor SC560 minimized 
Ang II-salt-induced hypertension which is associated with 
the increased sympathetic activity.32 Decrease in COX-2 
expression by IL-10 in PVN is related to reduced neuronal 
sympathetic excitation in heart failure in rats after myo-
cardial infarction.35 On the other hand, proinflammatory 
cytokines stimulate COX-2 expression in perivascular mac-
rophages,36 and when injected in the SFO increase BP, heart 
rate, and renal sympathetic activity.37 Therefore, Ang II via 
production of proinflammatory cytokines could increase 
COX activity and PGE2 synthesis. Reduction in COX-1 
and COX-2 expression by their respective siRNA in PVN 
also reduces deoxycorticosterone-induced hypertension.38 
COX-generated AA metabolite PGE2 injected into the cer-
ebroventricular system24,25 or rostral ventrolateral medulla26 
increases BP and sympathetic activity via EP3 receptors, 
respectively.25,26 Ang II-induced increase in BP is inhibited 
in both EP1 and EP3 receptor knockout mice or by EP1 and 
EP3 receptor antagonists.19,21 PGE2 generated by COX-1 in 
the SFO via the EP1 receptor is required for ROS genera-
tion and hypertension caused by Ang II.33 AA-metabolizing 
enzymes are constitutively active, and the rate-limiting step 
in the production of eicosanoids is the availability of AA. 
Therefore, cPLA2α activation by Ang II in the SFO appears 
to be critical for AA release resulting in the production of 
PGE2, and generation of ROS and ER stress that increases 
BP and results in cardiac and renal fibrosis. The contribution 
in Ang II-induced hypertension of cPLA2α in the PVN and 
rostral ventrolateral medulla where PGE2 via EP3 recep-
tors increases BP25,26 remains to be investigated and is one 
of the limitations of the present study. Like in our study in 
cPLA2α−/− mice, the COX1 or EP1 receptor gene disruption 
Figure 4. Ang II increases endoplasmic reticulum (ER) stress marker expression in the subfornical organ (SFO) of BALB/c cPLA2α+/+ but not cPLA2α−/− 
mice. RNA was isolated from SFO, and real-time PCR (RT-PCR) was performed for glucose-related protein 78 (GRP78), and C/EBP homologous protein 
(CHOP). (a) mRNA expression of GRP78 and CHOP in SFO of cPLA2α+/+ mice. (b) mRNA expression of GRP78 and CHOP in SFO of cPLA2α−/− mice. *P < 0.05, 
Ang II vs. Veh (vehicle) (n = 4). Data are expressed as mean ± SEM.
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or the central administration of their pharmacological 
inhibitors attenuated the increase in BP produced byAng 
II (600 ng/kg/min)33 that was comparable to that obtained 
in the present study. At present, we have no explanation 
how the central cPLA2α/COX1/EP1 receptor in SFO masks 
the direct vasconstrictor effect of Ang II. Further studies 
are required to determine if alteration in cPLA2α/COX/EP 
receptors in SFO and other brain areas also prevent the effect 
of bolus injections or short-term infusion of Ang II.
An important finding in our study was that Ang II also 
failed to increase BP in the partially cPLA2α gene-disrupted 
mice (cPLA2α+/−) expressing reduced cPLA2α mRNA in the 
heart, kidney, and SFO in C57BL/6 mice. These observations 
further support the critical role of cPLA2α in Ang II-induced 
hypertension. Further studies on different levels of cPLA2α 
expression or its copy number in the SFO and other tissues 
should allow the determination of its relationship to BP in 
various models of hypertension and associated pathogen-
esis. cPLA2α gene disruption also prevented hypertension 
produced by the inhibitor of nitric oxide synthesis, L-NG-
nitroarginine methyl ester,39 that is dependent on Ang II.40 
Our preliminary data obtained in C57BL/6 mice showed 
that cPLA2α gene disruption abolished deoxycorticosterone-
acetate-salt-induced hypertension and associated cardiac and 
renal fibrosis (C Y Song and K U Malik, unpublished results).
In conclusion, this study demonstrates that cPLA2α in 
the SFO is crucial in mediating the effect of systemic Ang 
II to cause ROS production and ER stress and hypertension, 
most likely by releasing AA and metabolizing it via COX 
producing PGE2. Our finding that the partial cPLA2α gene 
disruption (cPLA2α+/− mice) also prevented Ang II-induced 
hypertension supports the notion that cPLA2α activation is 
pivotal for the development of Ang II-induced hypertension. 
Therefore, development of selective orally active inhibitors 
of cPLA2α could be useful in the treatment of hypertension 
and its pathogenesis.
SUPPLEMENTARY MATERIAL
Supplementary materials are available at American Journal 
of Hypertension online.
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